Purdue Pharmaceuticals, L.P.
One Stamford Forum
About Purdue Pharmaceuticals, L.P.
Purdue Pharmaceuticals, L.P., headquartered in Stamford, CT, is a privately held pharmaceutical company founded by physicians and focused on meeting the needs of healthcare providers and the patients in their care. Together with its independent associated companies, Purdue is dedicated to finding, developing, and bringing to market new medicines and related products that improve health outcomes. The company has long been known for its pioneering research on persistent pain, a principal cause of human suffering.
Purdue also has a growing line of non-prescription products including laxatives, microbicides, and nutraceuticals. The company is dedicated to serving the evolving needs of healthcare providers, patients, and caregivers with prescription and non-prescription medicines. A commitment to innovation and caring spans every aspect of the organization, from discovering and launching new medicines to demonstrating their medical value.
Purdue has led the battle against inadequate treatment of pain by developing sustained-release medications to manage pain. Its sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to pain management.
In 1993, Purdue established Partners Against Pain® as a resource to help patients, caregivers, and healthcare professionals advance standards of pain care and alleviate unnecessary suffering through education and advocacy. Purdue has also assumed a leading role in addressing the serious public health problem of prescription drug abuse, supporting programs intended to help stem abuse.
At its research facilities in Cranbury, New Jersey, Purdue scientists are discovering new compounds to treat pain and developing formulations and delivery systems to help improve patient safety.
219 articles with Purdue Pharmaceuticals, L.P.
The Oklahoma Supreme Court has overturned the landmark $465 million opioid verdict handed down against Johnson & Johnson in 2019.
Scientists are making progress toward a vaccine that could help protect against deadly overdoses.
A trustee with the DOJ filed a request for an “expedited stay” in order to prevent the initiation of the bankruptcy plan.
The Sacklers did not admit to any wrongdoing and have never been charged directly for the issue. Still, Purdue Pharma has pleaded guilty twice in its erroneous marketing efforts for OxyContin.
A Sackler family heir said in a court appearance that the family, which owns OxyContin drug maker Purdue Pharma, holds a “moral responsibility” to lend its help in combating the U.S. opioid crisis but noted it will not give billions of dollars to a legal settlement unless broad legal protections ...
The move by the 15 states' attorneys general comes about a month ahead of a court hearing set for Aug. 5.
Purdue Pharma L.P. filed a Chapter 11 plan of reorganization and a related disclosure statement in the United States Bankruptcy Court for the Southern District of New York.
In their first appearance in years, the notorious Sackler family, who previously headed OxyContin maker Purdue Pharma, apologized to victims of the opioid crisis but stopped short of admitting personal responsibility during a nearly four-hour grilling from the U.S. House Oversight and Reform Comm...
Days after Purdue Pharma reached a combined $8.4 billion criminal and civil settlement with the U.S. Department of Justice, the OxyContin drugmaker pleaded guilty to three criminal charges to resolve its role in the ongoing opioid crisis in the United States.
A settlement valued at $8.34 billion was reached between Purdue Pharma and the Justice Department on Tuesday, which required the drug company to plead guilty to three felonies related to its marketing and distribution of OxyContin.
- Agreement resolves DOJ investigations into past marketing practices - Settlement funds primarily directed to state, local and tribal governments for opioid crisis abatement purposes - Agreement brings Purdue closer to its ultimate goal of delivering more than $10 billion in value to address the opioid crisis
The settlement stems from multi-year criminal and civil investigations into Purdue’s marketing practices related to its powerful prescription painkiller, OxyContin, which critics have argued facilitated the opioid epidemic.
The U.S. government is seeking $11 billion in civil and criminal penalties from Purdue Pharma as the maker of OxyContin winds its way through bankruptcy.
Purdue Pharma’s Avrio Health Donates Betadine® Antiseptic Products to Direct Relief for Use by Frontline Healthcare Workers
Avrio Health L.P., a subsidiary of Purdue Pharma L.P., has donated shipments of Betadine Solution and Surgical Scrub to Direct Relief, advancing the company’s previous commitment to donate $1.6 million worth of Betadine antiseptic products for use by frontline healthcare workers.
In light of the ongoing COVID-19 pandemic, the U.S. Bankruptcy Court for the Southern District of New York has granted a 30-day extension of the deadline to file a claim against Purdue Pharma L.P.,1 including claims related to Purdue prescription opioids, like OxyContin.2 The new deadline or "bar date" is Thursday, July 30, 2020, at 5:00 p.m..
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
Purdue Pharma’s Avrio Health Begins Studies Assessing Betadine® (Povidone-Iodine) Antiseptic Products’ Safety and Effectiveness Against COVID-19
Program complements ongoing efforts to build understanding of potential virucidal properties of povidone-iodine against the virus causing COVID-19
Purdue Pharma’s Avrio Health Donates $1.6 Million Worth of Betadine® Antiseptic Products for Use by Frontline Healthcare Workers
Purdue Pharma’s Avrio Health Donates $1.6 Million Worth of Betadine ® Antiseptic Products for Use by Frontline Healthcare Workers
Those Who Believe They Have a Claim Against Purdue Must File a Proof of Claim by the Bar Date: June 30, 2020
Purdue Pharma L.P., a U.S. limited partnership, its general partner and its subsidiaries, including Imbrium Therapeutics L.P., Adlon Therapeutics L.P., Greenfield BioVentures L.P., Avrio Health L.P., Rhodes Technologies, and Rhodes Pharmaceuticals L.P., filed for bankruptcy in September 2019.
Purdue Taps Tom Vilsack, Former Cabinet Secretary and Governor, to Monitor Compliance With Voluntary Injunction
Feb. 21, 2020 15:13 UTC STAMFORD, Conn.--( BUSINESS WIRE )-- Purdue Pharma L.P. (“Purdue”) today announced the appointment of former United States Agriculture Secretary and Iowa Governor Tom Vilsack as Monitor under the voluntary self-injunction approved on November 6, 2019, in its chapter 11 bankruptcy case. In its initial bankruptcy filings, Purdue voluntarily proposed to formalize under court order its commitment to continue to refrain from engaging in certain promotional